Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to $6.4 million.

  • Lifecore Biomedical's Cash from Financing Activities rose 34.53% to -$402,000 in Q2 2025 from the same period last year, while for May 2025 it was $6.4 million, marking a year-over-year decrease of 14.45%. This contributed to the annual value of $6.4 million for FY2025, which is 14.45% down from last year.
  • Per Lifecore Biomedical's latest filing, its Cash from Financing Activities stood at $6.4 million for FY2025, which was down 14.45% from $7.5 million recorded in FY2024.
  • In the past 5 years, Lifecore Biomedical's Cash from Financing Activities registered a high of $39.7 million during FY2023, and its lowest value of -$57.0 million during FY2022.
  • For the 3-year period, Lifecore Biomedical's Cash from Financing Activities averaged around $17.9 million, with its median value being $7.5 million (2024).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first slumped by 1,567.77% in 2022, then skyrocketed by 169.62% in 2023.
  • Lifecore Biomedical's Cash from Financing Activities (Yearly) stood at -$3.4 million in 2021, then tumbled by 1,567.77% to -$57.0 million in 2022, then soared by 169.62% to $39.7 million in 2023, then plummeted by 81.09% to $7.5 million in 2024, then declined by 14.45% to $6.4 million in 2025.